Skip to main content
NCBI home page
The Journal of Experimental Medicine logoLink to The Journal of Experimental Medicine
. 1988 Jun 1;167(6):1981–1986. doi: 10.1084/jem.167.6.1981

Anti-interleukin 2 receptor monoclonal antibodies spare phenotypically distinct T suppressor cells in vivo and exert synergistic biological effects

PMCID: PMC2189695  PMID: 2968435

Abstract

The therapeutic efficacies of ART-18, ART-65, and OX-39, mouse antibodies of IgG1 isotype recognizing distinct epitopes of the p55 beta chain of the rat IL-2-R molecule, were probed in LEW rat recipients of (LEW X BN)F1 heterotopic cardiac allografts (acute rejection in untreated hosts occurs within 8 d). A 10-d course with ART- 18 prolongs graft survival to approximately 21 d (p less than 0.001). Therapy with ART-65, but not with OX-39, was effective (graft survival approximately 16 and 8 d, respectively). Anti-IL-2-R mAb treatment selectively spared T cells with donor-specific suppressor functions; the CD8+ (OX8+ W3/25-) fraction from ART-18-modified recipients, and primarily the CD4+ (W3/25+ OX8-) subset from ART-65-treated hosts conferred unresponsiveness to naive syngeneic rats after adoptive transfer, increasing test graft survival to approximately 16 and 45 d, respectively. Concomitant administration of ART-18 and ART-65 to recipient animals in relatively low doses exerted a strikingly synergistic effect, with 30% of the transplants surviving indefinitely and 50% undergoing late rejection over 50 d. These studies provide evidence that anti-IL-2-R mAbs selectively spare phenotypically distinct T cells with suppressor functions. The data also suggest that in vivo targeting of functionally different IL-2-R epitopes may produce synergistic biological effects.

Full Text

The Full Text of this article is available as a PDF (410.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bolton A. E., Hunter W. M. The labelling of proteins to high specific radioactivities by conjugation to a 125I-containing acylating agent. Biochem J. 1973 Jul;133(3):529–539. doi: 10.1042/bj1330529. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Diamantstein T., Osawa H., Kirkman R. L., Shapiro M. E., Strom T. B., Tilney N. L., Kupiec-Weglinski J. W. Interleukin 2 receptor--a target for immunosuppressive therapy. Transplant Rev (Orlando) 1987;1:177–196. doi: 10.1016/s0955-470x(87)80011-3. [DOI] [PubMed] [Google Scholar]
  3. Duarte A. J., Carpenter C. B., Strom T. B. Expression of T cell differentiation antigens and Ia on rat cytotoxic T lymphocytes. J Immunol. 1982 Feb;128(2):580–584. [PubMed] [Google Scholar]
  4. Kelley V. E., Gaulton G. N., Strom T. B. Inhibitory effects of anti-interleukin 2 receptor and anti-L3T4 antibodies on delayed type hypersensitivity: the role of complement and epitope. J Immunol. 1987 May 1;138(9):2771–2775. [PubMed] [Google Scholar]
  5. Kupiec-Weglinski J. W., Di Stefano R., Stunkel K. G., Grutzmann R., Theisen P., Araneda D., Tilney N. L., Diamantstein T. Anti-interleukin 2 receptor monoclonal antibody therapy in rat recipients of cardiac allografts: the role of antibody isotype. Transplant Proc. 1988 Feb;20(1 Suppl 1):272–275. [PubMed] [Google Scholar]
  6. Kupiec-Weglinski J. W., Diamantstein T., Tilney N. L., Strom T. B. Therapy with monoclonal antibody to interleukin 2 receptor spares suppressor T cells and prevents or reverses acute allograft rejection in rats. Proc Natl Acad Sci U S A. 1986 Apr;83(8):2624–2627. doi: 10.1073/pnas.83.8.2624. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Kupiec-Weglinski J. W., Padberg W., Uhteg L. C., Ma L., Lord R. H., Araneda D., Strom T. B., Diamantstein T., Tilney N. L. Selective immunosuppression with anti-interleukin 2 receptor-targeted therapy: helper and suppressor cell activity in rat recipients of cardiac allografts. Eur J Immunol. 1987 Mar;17(3):313–319. doi: 10.1002/eji.1830170303. [DOI] [PubMed] [Google Scholar]
  8. Kupiec-Weglinski J. W., Padberg W., Uhteg L. C., Towpik E., Lord R. H., Ma L., Diamantstein T., Strom T. B., Tilney N. L. Anti-interleukin-2 receptor (IL-2R) antibody against rejection of organ grafts. Transplant Proc. 1987 Feb;19(1 Pt 1):591–593. [PubMed] [Google Scholar]
  9. Leonard W. J., Depper J. M., Kanehisa M., Krönke M., Peffer N. J., Svetlik P. B., Sullivan M., Greene W. C. Structure of the human interleukin-2 receptor gene. Science. 1985 Nov 8;230(4726):633–639. doi: 10.1126/science.2996141. [DOI] [PubMed] [Google Scholar]
  10. Mouzaki A., Diamantstein T. Four epitopes on the rat 55-kDa subunit of the interleukin 2 receptor as defined by newly developed mouse anti-rat interleukin 2 receptor monoclonal antibodies. Eur J Immunol. 1987 Nov;17(11):1661–1664. doi: 10.1002/eji.1830171123. [DOI] [PubMed] [Google Scholar]
  11. Mouzaki A., Volk H. D., Osawa H., Diamantstein T. Blocking of interleukin 2 (IL 2) binding to the IL 2 receptor is not required for the in vivo action of anti-IL 2 receptor monoclonal antibody (mAb). I. The production, characterization and in vivo properties of a new mouse anti-rat IL 2 receptor mAb that reacts with an epitope different to the one that binds to IL 2 and the mAb ART-18. Eur J Immunol. 1987 Mar;17(3):335–341. doi: 10.1002/eji.1830170306. [DOI] [PubMed] [Google Scholar]
  12. Osawa H., Diamantstein T. The characteristics of a monoclonal antibody that binds specifically to rat T lymphoblasts and inhibits IL 2 receptor functions. J Immunol. 1983 Jan;130(1):51–55. [PubMed] [Google Scholar]
  13. Paterson D. J., Jefferies W. A., Green J. R., Brandon M. R., Corthesy P., Puklavec M., Williams A. F. Antigens of activated rat T lymphocytes including a molecule of 50,000 Mr detected only on CD4 positive T blasts. Mol Immunol. 1987 Dec;24(12):1281–1290. doi: 10.1016/0161-5890(87)90122-2. [DOI] [PubMed] [Google Scholar]
  14. Shimuzu A., Kondo S., Takeda S., Yodoi J., Ishida N., Sabe H., Osawa H., Diamantstein T., Nikaido T., Honjo T. Nucleotide sequence of mouse IL-2 receptor cDNA and its comparison with the human IL-2 receptor sequence. Nucleic Acids Res. 1985 Mar 11;13(5):1505–1516. doi: 10.1093/nar/13.5.1505. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Smith K. A. Interleukin 2. Annu Rev Immunol. 1984;2:319–333. doi: 10.1146/annurev.iy.02.040184.001535. [DOI] [PubMed] [Google Scholar]
  16. Soulillou J. P., Peyronnet P., Le Mauff B., Hourmant M., Olive D., Mawas C., Delaage M., Hirn M., Jacques Y. Prevention of rejection of kidney transplants by monoclonal antibody directed against interleukin 2. Lancet. 1987 Jun 13;1(8546):1339–1342. doi: 10.1016/s0140-6736(87)90648-9. [DOI] [PubMed] [Google Scholar]

Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press

RESOURCES